Abstract
Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 × 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 395-401 |
| Number of pages | 7 |
| Journal | Gynecologic Oncology |
| Volume | 34 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1989 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology
Fingerprint
Dive into the research topics of 'Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver